🏛️ Verified NIH Record • Updated 2026-04-08
Monthly Dosing of Atacicept in IgAN (NCT07020923)
A Study Evaluating Monthly (Every 4 Weeks) Dosing of Atacicept in Patients With IgAN
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Vera Therapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, open-label, multicenter, randomized study comprising parallel groups of participants receiving weekly and/or monthly doses of atacicept
Who can join: Review the eligibility criteria below.
Location: Vera Therapeutics — Brisbane, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Vera Therapeutics — Brisbane, California
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in IgA Nephropathy (IgAN)
- Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN) — Jacksonville, Florida
Explore by condition: All IgA Nephropathy (IgAN) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.